Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Price to Earnings (P/E)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Bristol-Myers Squibb Co., P/E, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$

2 Data adjusted for splits and stock dividends.

3 Closing price as at the filing date of Bristol-Myers Squibb Co. Annual Report.


The share price exhibits considerable variability over the periods analyzed. Starting at $22.91 in 2006, it generally increased with intermittent fluctuations, reaching peaks near $60 between 2014 and 2016. After a dip around 2018 to 2019, the price recovered and peaked at $72.25 in 2023, followed by a notable decline to $48.71 in 2024, and then a moderate recovery to $56.15 in 2025. This pattern suggests periods of growth interrupted by volatility, likely influenced by external market conditions and company performance factors.

Earnings per share (EPS) show a highly volatile pattern throughout the years. EPS began at $1.53 in 2006, with sharp fluctuations such as the surge to $6.19 in 2010, followed by declines and subsequent rebounds. Noteworthy is the negative EPS recorded in 2021 (-$4.02) and 2025 (-$4.41), indicating losses during those years. Between these, EPS experienced recovery and growth phases, reaching highs of around $3.97 in 2024. The erratic EPS trend points to inconsistent profitability and potential operational challenges or one-time charges that impacted earnings.

The price-to-earnings (P/E) ratio, calculated as the share price divided by EPS, reflects the fluctuations in both earnings and market valuation. The ratio started at 14.96 in 2006, rising sharply to values above 30 several times, and even reaching 103.55 in 2018, indicating periods when the market priced the stock very aggressively relative to earnings. The P/E ratio shows substantial increases during years of low or depressed EPS, amplifying valuation multiples. Missing P/E values for some years align with negative EPS, where P/E is not meaningful. The overall P/E trend suggests periods of high investor optimism and times when earnings dipped significantly, affecting valuation metrics.


Comparison to Competitors

Bristol-Myers Squibb Co., P/E, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Bristol-Myers Squibb Co., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)